(Term expires November 12, 2021)
Mehmood Khan, is the Chief Executive Officer of Hevolution Foundation, a first of its kind non-profit organization that funds research through grants and provides investments in biotech to incentivize healthspan science across disciplines and borders for the benefit of all. Established by a Saudi Royal Decree with its headquarters in Riyadh with additional international hubs to support the expansion and execute the global mission. Its vision is to expand healthy human lifespan for the benefit of all humanity. Hevolution Foundation aims to be positioned as a global leader, catalyst, partner, and convener, to increase the number of scientists entering the field, to increase the investable opportunities in the field of aging, to help shape the regulatory and government environment.
He also currently serves as the Executive Chairman of Life Biosciences Inc. where he joined the company in April 2019 as the Chief Executive Officer and Board Member. Life Biosciences was founded to advance scientific research and develop innovative new therapies to improve and extend healthy lives for everyone.
Dr. Khan previously served as Vice Chairman and Chief Scientific Officer of Global Research and Development at PepsiCo, a Fortune 50 company employing upwards of 250,000 employees across 22 brands. At PepsiCo, Dr. Khan played a pivotal role in the company’s global R&D efforts to create breakthrough innovations in food, beverages, and nutrition, including the incorporation of healthier and more nutritious offerings across its portfolio. Dr. Khan also oversaw PepsiCo's global sustainability initiatives based on the belief that success in business is inextricably linked to the sustainability of the world we share. Prior to joining PepsiCo, Dr. Khan served as President of Global R&D at Takeda Pharmaceuticals, leading the global efforts of one of the largest pharmaceutical companies in the world by revenue.
Before moving into industry, Dr. Khan had a distinguished medical career as a faculty member in endocrinology at the Mayo Clinic and Mayo Medical School where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit. He also spent nine years leading programs in diabetes, endocrinology, metabolism and nutrition in Minneapolis, MN.
Dr. Khan is currently a member of the Board of Directors of Reckitt Benckiser.
Dr. Khan has also served as a board member in Spectrum Health, CorMedix, HemoShear Therapeutics, and Indigo Agriculture.
Dr. Khan earned his medical degree from the University of Liverpool Medical School, England, and completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota, Minneapolis. He is a Fellow of the Royal College of Physicians in London and a Fellow of the American College of Endocrinology.